Contact
searchSearch
HMP Global
Login

November/December 2015

Feature

Perspectives
Formulary Decisions and the Evolution of Psoriasis Treatment
12/14/2015
Steven R. Feldman, MD, PhD; William Malatestinic, PharmD, MBA; David Amato, MD
Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...
Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...
...
12/14/2015
Journal of Clinical Pathways
Research Reports
A Clinical Pathway to Reduce Time to Antibiotic Administration in Pediatric Cancer Patients With Fever and Potential Neutropenia
12/14/2015
Susan Lindemulder, MD, MCR; Thuan Nguyen, MD, PhD; Adam Lamble, MD; David M. Spiro, MD, MPH; Dawn Nolt, MD, MPH; Linda C. Stork, MD; Suman Malempati, MD
Abstract:  The authors developed a novel clinical pathway in the pediatric emergency department (PED) of Doernbecher Children’s Hospital, Oregon Health & Science University, that endorses administering...
Abstract:  The authors developed a novel clinical pathway in the pediatric emergency department (PED) of Doernbecher Children’s Hospital, Oregon Health & Science University, that endorses administering...
...
12/14/2015
Journal of Clinical Pathways

Column

Counterpoint
When Determining Value in Cancer Care, Don`t Forget the Patient
12/14/2015
Joan S. McClure, MS; Al B. Benson, III, MD, FACP, FASCO
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only...
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only...
...
12/14/2015
Journal of Clinical Pathways
Viewpoint
Overcoming the Political and Economic Roadblocks Stopping Effective Comparative Drug Evaluation
12/14/2015
Roger Longman, MA
Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of the resistance of drug companies and payers, stakeholders are finding other tools to help...
Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of the resistance of drug companies and payers, stakeholders are finding other tools to help...
...
12/14/2015
Journal of Clinical Pathways
Clinical Pathways GPS
The Place for Biosimilars in Clinical Pathways
12/14/2015
Scott Guerin, PhD; Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...
Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...
...
12/14/2015
Journal of Clinical Pathways

Insights

Interview
A Clinical Pathway for Transcatheter Aortic Valve Replacement
12/14/2015
More and more, various health care institutions around the country are implementing clinical pathways in an effort to improve outcomes and control costs. A 2003 study reported that more than 80% of hospitals had implemented clinical...
More and more, various health care institutions around the country are implementing clinical pathways in an effort to improve outcomes and control costs. A 2003 study reported that more than 80% of hospitals had implemented clinical...
More and more, various...
12/14/2015
Journal of Clinical Pathways
Interview
Evidence Blocks to Evaluate the Relative Value of Oncology Treatments
12/14/2015
Many institutions and health care professionals have been aware of the staggering rise of health care costs. An IMS Health report published in May of 2015 confirmed that drug sales in the United States surpassed...
Many institutions and health care professionals have been aware of the staggering rise of health care costs. An IMS Health report published in May of 2015 confirmed that drug sales in the United States surpassed...
Many...
12/14/2015
Journal of Clinical Pathways

Department

Research in Review
Routine Imaging for DLBCL Post-Remission Does Not Improve Survival
12/14/2015
Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...
Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...
...
12/14/2015
Journal of Clinical Pathways
Research in Review
Circulating Tumor DNA in Blood Used to Track Cancer Treatment Outcomes
12/11/2015
Two new studies suggest a role for blood tests, or liquid biopsies, in guiding a patient’s cancer treatment. The research, which involved patients with breast and prostate cancers, scanned blood for traces of...
Two new studies suggest a role for blood tests, or liquid biopsies, in guiding a patient’s cancer treatment. The research, which involved patients with breast and prostate cancers, scanned blood for traces of...
Two...
12/11/2015
Journal of Clinical Pathways
Research in Review
ASCO Updates Antiemetic Guidelines to Include New Agent
12/11/2015
The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...
The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...
The...
12/11/2015
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

November 2015 Volume 1

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use